We observed an EGFR mutation frequency of 24.0% among the adenocarcinoma stage IV patients, in line with previous Brazilian estimates (3), which was higher than that in North America and Europe (for which EGFRm frequencies usually range from 10-20%) and lower than that in Asia (as high as 50%) (15). This evidence concerns the gene EGFR and adenocarcinoma.